People-Powered Medicine

RANT Study

“RANT” stands for Rheumatoid Arthritis Non-responders to Treatments.

We are interested in understanding why rheumatoid arthritis (RA) therapies work for some patients and not others. In this study, we would like to hear from RA patients who have tried two or more biologic and targeted therapies and to obtain more information on why they did not work. Please see below for a list of the RA biologic and targeted therapies.

Many conditions are being redefined as scientific advancements improve our ability to study underlying genetics and pathways. Studying RA patients who do not respond to biologic therapy will help us to understand why you may be different and help us to discover different pathways to target for therapy. In turn, this can inform our ability to treat patients with RA with more precision medicine and ultimately improve the management and lives of patients with inflammatory arthritis in the future.

Who Can Volunteer

Non-responders include RA patients who had active disease despite receiving at least two of the following biologic or targeted RA therapies:

• tocilizumab (Actemra)
• certolizumab (Cimzia)
• etanercept (Enbrel)
• adalimumab (Humira)
• sarilumab (Kevzara)
• anakinra (Kineret)
• baricitinib (Olumiant)
• abatacept (Orencia)
• infliximab (Remicade)
• upadacitinib (Rinvoq)
• rituximab (Rituxan)
• golimumab (Simponi)
• tofacitinib (Xeljanz)